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Stem cells, through their ability to both self-renew
and differentiate, can produce a virtually limitless
supply of specialized cells that behave comparably
to primary cells. We took advantage of this property
to develop an assay for small-molecule-based neu-
roprotection using stem-cell-derived motor neurons
and astrocytes, together with activated microglia as
a stress paradigm. Here, we report on the discovery
of hit compounds from a screen of more than 10,000
small molecules. These compounds act through
diverse pathways, including the inhibition of nitric
oxide production by microglia, activation of the
Nrf2 pathway in microglia and astrocytes, and direct
protection of neurons from nitric-oxide-induced
degeneration. We confirm the activity of these
compounds using human neurons. Because micro-
glial cells are activated in many neurological disor-
ders, our hit compounds could be ideal starting
points for the development of new drugs to treat
various neurodegenerative and neurological
diseases.
INTRODUCTION
Stem cells have the unique ability to both continually self-renew
and differentiate into specialized cells. Pluripotent stem cells
have the largest developmental potential because they are
capable of differentiating into every somatic cell lineage as well
as germ cells. For example, Wichterle and colleagues provided
the first evidence for the efficient and direct generation of mouse
embryonic stem cells (ESCs) intomotor neurons (MNs;Wichterle
et al., 2002). These cells were electrophysiologically functional
and capable of restoring voluntary movement after transplanta-620 Cell Stem Cell 11, 620–632, November 2, 2012 ª2012 Elsevier Intion into rats paralyzed by a viral infection that had killed their
MNs (Deshpande et al., 2006). Multipotent stem cells have
a more restricted differentiation potential, as they are capable
of differentiating into a limited number of specialized cell types.
For example, neural stem cells (NSCs) have the potential to
differentiate into three cell types: neurons, astrocytes, and oligo-
dendrocytes. By the expansion of stem cells in culture through
their ability to self-renew followed by their directed differentiation
into particular cell lineages, it is possible to obtain large numbers
of stem cells that can be differentiated into a wide range of cell
types in vitro whose function is comparable to that of primary
cells. Such large quantities of specialized cells enable
researchers to conduct new types of experiments into develop-
mental biology as well as to test new possible therapeutic strat-
egies that may lead to drug discovery.
The 21st century has seen a strong increase in the discovery of
first-in-class drugs with new molecular mechanisms of action
(MMOA), arising from phenotypic screening methodologies
(Swinney and Anthony, 2011). In fact, between 1999 and 2008,
the contribution of phenotypic screening to the discovery of
first-in-class small molecule drugs exceeded that of target-
based approaches; target-based approaches were the most
successful for the discovery of follower drugs. Although primary
cells would be the ideal cell type for phenotypic screening, the
isolation of primary cells is extremely cumbersome, giving both
low yields and heterogeneous results, making a high-throughput
screening (HTS) campaign almost impossible. In addition,
although cell lines are readily expandable, their phenotype is
markedly different from that of primary cells, which makes their
use in screening questionable. In contrast, stem cells can
provide large numbers of homogeneous cells with a defined
stage of differentiation and maturation (McNeish et al., 2010).
Therefore, using stem cell technology, it is theoretically possible
not only to construct disease models in vitro, but also to use
these models to discover new drug candidates, representing
a new paradigm for drug discovery.
Neurodegenerative diseases, such as amyotrophic lateral
sclerosis (ALS), Parkinson’s disease, and Alzheimer’s disease,c.
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neurons within the central nervous system. Increasing evidence
indicates that abnormal activation ofmicroglial cells, the resident
immune cells of the central nervous system, plays an important
role in the pathogenesis of neurodegeneration. Activation of
microglial cells correlates well with the clinical pathology of neu-
rodegeneration (Hall et al., 1998; Henkel et al., 2004; Kawamata
et al., 1992; Turner et al., 2004). In a transgenic animal model of
the motor neurodegenerative disease ALS, stimulation of micro-
glial cells, such as with lipopolysaccharide (LPS), was found to
exacerbate disease pathology, whereas inhibition of microglial
activation increased survival (Kriz et al., 2002; Nguyen et al.,
2004). On the other hand, microglial activation can have neuro-
protective, rather than neurotoxic, effects. Under appropriate
conditions, activated microglial cells secrete a mixture of neuro-
protective factors, including brain-derived neurotrophic factor
(BDNF), glial-cell-derived neurotrophic factor (GDNF), and
neurotrophin-4 (NT4) (Hanisch and Kettenmann, 2007). Further-
more, microglial cells have been shown to influence the migra-
tion and differentiation of neural precursor cells (Aarum et al.,
2003). Therefore, neurodegeneration associated with microglial
activation is a complex phenotype with many different possible
targets for new drug candidates. We postulate that a stem-
cell-based assay is capable of recapitulating the spectrum of
targets and effects that are therapeutically relevant to neurode-
generative diseases in humans.
We have developed a stem-cell-based model of motor neuron
degeneration induced by microglial activation. This is an excel-
lent model to demonstrate proof of concept for HTS for several
reasons. First, although microglial cells have a significant role
in many neurological disorders, their direct involvement in
inducing neurodegeneration is probably best demonstrated in
a transgenic mouse model of ALS (Boille´e et al., 2006). As
such, motor neurons are the most appropriate system for initial
discovery of inhibitors of toxicity induced by microglial activa-
tion. However, such inhibitors could clearly be protective of other
neuronal subtypes, as microglial activation is a hallmark of many
neurodegenerative diseases. Second, the unique properties of
stem cells enabled us to derive the large numbers of motor
neurons needed for screening from a single batch of stem cells,
which would not be possible with primary motor neurons, which
are cumbersome to isolate and result in low yields. A true HTS
using primary motor neurons would necessitate the usage of
enormous-number batches of primary motor neurons, which is
impractical. While neuronal cell lines are significantly more prolif-
erative and, therefore, amenable to HTS, they have been shown
to behave significantly differently from primary neurons (Czvitko-
vich et al., 2011). In contrast, ESC-derived motor neurons have
been demonstrated to be functional and are even able to regen-
erate motor connections in paralyzed rodents, which demon-
strates that their behavior mirrors that of primary motor neurons
(Deshpande et al., 2006; Miles et al., 2004). Here, we report the
generation of a stem-cell-based phenotypic assay that is suit-
able for HTS. We report on the discovery of compounds acting
through multiple pathways, and confirm their activity using
human neurons. We use in silico analysis to predict that our hit
compounds are metabolically stable and able to cross both the
intestinal epithelium and blood-brain barrier (BBB), which
suggests that our hit compounds could be of interest in theCelldevelopment of therapeutic agents for many neurodegenerative
and neurological diseases.
RESULTS
Assay Design and Development of HTS Platform
To enable HTS for microglial toxicity, we first developed a stem-
cell-derived coculture system of astrocytes andMNs (Figure 1A).
ESCs were derived from mice that contained a bacterial artificial
chromosome (BAC)-based Hb9-green fluorescent protein (GFP)
reporter vector (GENSAT GX229), which is expressed in postmi-
totic MNs (Figure S1 available online). These ESCs were
expanded and differentiated into MNs (Figure S1), and were
then isolated by fluorescence activated cell sorting (FACS).
The differentiation medium and dissociation conditions were
optimized for a maximal yield of highly GFP-expressing cells,
which averaged 14% (Figure 1B). Gene expression analysis for
Islet-1 confirmed that these cells were indeed MNs (Figure 1B).
MNsareknown tobedependenton trophic support for survival,
and primary astrocytes are commonly used to sustain them in
coculture. Although cortical astrocytes are available, directing
the differentiation of NSCs into astrocytes is straightforward, effi-
cient, and reproducible, and reduces animal handling and sacri-
fice. Therefore, astrocytes were differentiated from NSCs. On
day 4 of differentiation, the astrocytes were seeded into Matri-
gel-coated 384-well plates. These astrocytes were then matured
on-plate for increasingperiodsof timeand tested for their ability to
sustainMNsurvival after FACS. Fourteendaysofmaturationgave
a robust MN survival after FACS isolation, which was used for
further assaydevelopmentandscreening (Figure1C).MNsurvival
was quantified using high-content imaging for multiple readouts
including total neurite length per well, total number of branch
points per well, and total neurite area per well, based on the
morphology of GFP-expressing MNs. Total neurite length per
well resulted in the most favorable statistical significance, and
we therefore used this readout throughout the remainder of the
experiments. Althoughwe expected to observe an initial increase
in neurite length, we consistently observed a plateau effect for the
first 4 days followed by significant cell death (Figure 1C). This is
likely due to the fact that a single quantitative readout obtained
for a well necessitated averaging all of these neurons, resulting
in a plateau of total neurite length per well. Because the MNs
have been isolated by FACS, they are under significant stress.
Therefore, the cultures contain a mixture of stressed cells and
healthy cells growing new axons. Similar curves were obtained
for the other parameters.
The cell line BV2 was used as a source of microglial cells for
several reasons. First, the isolation of primary mouse microglia
is impractical for HTS. Second,microglial cells cannot yet be effi-
ciently differentiated from an expandable stem cell source such
as ESCs. Third, BV2 cells are well characterized and behave
comparably to primary murine microglial cells with respect to
stimulation and cell to cell interactions (Blasi et al., 1990). We
tested the common stimuli interferon gamma (IFN-g) and LPS
for their ability to stimulate BV2 cells and found that the combi-
nation gave the most robust generation of nitric oxide (NO),
which is indicative of microglial activation (Figure 1D). Therefore,
we used BV2 cells stimulated with IFN-g and LPS for further
assay development and screening.Stem Cell 11, 620–632, November 2, 2012 ª2012 Elsevier Inc. 621
Figure 1. Development of HTS Platform
(A) Overview of the assay concept.
(B) Flow cytometric analysis of GFP induction by
cultures of ESCs after 6 days of differentiation into
MNs (left) and subsequent quantitative RT-PCR
for Islet1 expression (right).
(C) The astrocyte-MN coculture system: MN
survival was evaluated at indicated days after
FACS isolation and plating on astrocytes by high-
content imaging using neurite total length per well
as a readout (left), and a double fluorescent image
(right) for Gfap immunostaining (astrocytes) and
GFP (MNs).
(D) NO production after incubation of microglial
cells with the indicated stimuli.
(E) Neurodegeneration induced by microglial
activation for both cortical neurons (left) and
unsorted ESC-derived neurons (right).
All data are shown as mean ± SD. See also
Figure S1.
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cells to induce MN death by introducing them in coculture with
the MNs and astrocytes. We consistently observed MN death
within 28 hr of introducing the activated BV2 cells. Cell death
was not selective to MNs, as tested by costaining of the cells
with bIII-tubulin (Figure 1E) and by using primary cortical neurons
instead of stem-cell-derived MNs (Figure 1E). The coculture
model was scaled down to a 384-well format and assessed
with high-content imaging. The parameter neurite total length
per well measured an average of 3,461 units (with a standard
deviation of 1,208) and 41,149 (with a standard deviation of
5,543) when using activated and nonactivated microglial cells,
respectively. This resulted in a z-value score of 0.46, which is
indicative of a statistically robust assay.
Screening and Hit Profiling
To identify compounds that inhibited microglial toxicity, we
screened more than 10,000 compounds at 10 mM screening622 Cell Stem Cell 11, 620–632, November 2, 2012 ª2012 Elsevier Inc.concentration using the aforementioned
phenotypic assay. These compounds
were derived from several different
libraries containing known drugs or novel
chemical matter structurally enriched to
target various different target groups.
Active compounds were defined as
compounds that increased the survival
of MNs by at least 5 sigma above the
mean of low control level (0%). Survival
of MNs was defined as the total neurite
length of all neurites of the MNs in the
images captured from one well of the
sample normalized to controls and ex-
pressed as a percentage. Thirty-seven
active compounds were identified, repre-
senting a primary hit rate of 0.3% (Figures
2A–2CandTableS1). Throughastructural
similarity search, five of our primary hits
were found to be related to compoundsthat had previously been described in the context of inflamma-
tion or neuroprotection (Table S2). To determine if this was signif-
icant, we repeated the similarity search with 37 randomly
selected compounds. However, there was no overlapping target
information. Based on these data, we conclude that there is
a high likelihood that for 5 of 37 compounds there is a significant
enrichment.
We next identified hits among the active compounds. A hit was
defined as an active compound that produced a reproducible
EC50. We tested 34 of the 37 active compounds and identified
26 that showed a concentration-dependent and reproducible
effect (Figure 3 and Table S1). The observed inhibition of micro-
glia-mediated toxicity was not specific to MNs, as demonstrated
by using cortical neurons instead of stem-cell-derived MNs (Fig-
ure 3). All experiments hereinafter were conducted with
compound stocks that were repurchased from commercial
vendors, and not from the original compound library supply.
After reconfirmation of the repurchased compounds, a group
Figure 2. Identification of Active Compounds
(A) Summary of primary screening results shown as a dot plot of the normalized
assay signal values of the primary screening consisting of 11,819 tested
compounds. Active compounds, which increased MN survival by at least 5
sigma, are shown in red. MN survival was defined as the total neurite length of
all neurites of the MNs in the images captured from one well of the sample
normalized to the controls and expressed in percentages.
(B) List of library subsets and corresponding hit rates.
(C) Example plate from the primary screening, with 100% defined by the ‘‘High
control (H),’’ which consisted of nonactivated microglial cells, and 0% defined
by the ‘‘Low control (L),’’ which included activated microglial cells without any
additional small molecules. An active compound example is also shown (well
P6), showing 96% neuroprotection.
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tive hit compounds are shown in the sections below for each of
the different orthogonal assays.
A prerequisite for animal testing is that the compounds be
metabolically stable and able to cross both the intestinal epithe-Celllium and BBB. Previously, we developed in silico models that are
predictive of these properties. For metabolic stability, we used
a model that is predictive for being metabolized by cytochrome
P450 (CYP), which is responsible for about 75% of drug metab-
olism (Guengerich, 2008). For each of the tested hits, there were
no predictedmetabolites, suggesting that they are stable against
CYP-mediated degradation. Next, we assessed intestinal mem-
brane permeability using an in silico model that is predictive for
permeability across a layer of CACO-2 cells, which is currently
the industry standard. Only two of the tested compounds, E29
and E34, were associated with a predicted log of apparent
permeability (Papp) of less than 6, which indicates low perme-
ability. All other compoundswere predicted to be completely ab-
sorbed through the intestinal epithelium (Table S3). Finally, we
used two different prediction methods to assess the potential
of our hits to cross the BBB. Both predictions indicated that
most of our hit compounds are able to cross the BBB (Table
S3). Therefore, the hit compounds are generally predicted to
bemetabolically stable and bioavailable to neurons in the central
nervous system, which are necessary attributes for future drug
development.
Involvement of Microglial Cells in Neuroprotection
by Hit Compounds
To further validate the hit compounds, we sought to determine
the mechanism by which these compounds inhibited microglial
toxicity. One of the identified hits (E34) is a known inhibitor of
the nitric oxide synthase (NOS) L-NIO (Rees et al., 1990), andmi-
croglial activation is known to induce expression of NOS, which
catalyzes the production of NO. Other hit compounds might
similarly prevent microglial cells from producing toxic mediators
such as NO. Alternatively, a hit might directly target MNs and
protect them fromNO-induced toxicity. To discriminate between
these two modes of action, we substituted the activated micro-
glial cells with 200 mM of the NO donor diethylenetriamine/nitric
oxide (DetaNO), which efficiently induced MN death in our astro-
cyte-MN coculture system (Figure S2A). The results were directly
compared with the effects of using activated microglial cells as
toxic donors. If the hits inhibit microglial production of toxic
agents such as NO, then they would not rescue MNs from De-
taNO-induced death (Figure 4A). In contrast, hit compounds
acting on microglia would be expected to rescue MNs from
degeneration induced by activated microglial cells (Figure 4A).
Of the tested compounds, this latter profile was observed for
hit compounds E5, E14, E18, E19, E20, E21, E23, E25, E33,
and E34 (Figures 4B and S2B). As expected, higher concentra-
tions of hit compounds were usually toxic to MNs.
Next, we tested whether these hit compounds reduced NO
production by microglial cells under activation conditions, and
thereby protect (motor) neurons from degeneration. To test
this, we measured the amount of NO production by activated
BV2 cells in the presence of the hit compound using the Griess
reaction (Figures 4C, 4D, and S2C). E5, E14, E19, E20, E25,
E33, and E34 showed a dose-dependent decrease in NO
production with EC50 values comparable with their EC50 values
for MN rescue, which suggests that they inhibit production of
toxic mediators by microglial cells.
However, it is also possible that the hit compounds might be
selectively toxic to microglial cells, which would also reduceStem Cell 11, 620–632, November 2, 2012 ª2012 Elsevier Inc. 623
Figure 3. Identification of Hits
The neuroprotective effect and EC50 curves of four
hit compounds (examples from the total of 26 hit
compounds) are shown for both Hb9-GFP MNs
(middle panel) and cortical neurons (lower panel).
The respective EC50 values are listed in the
embedded tables. Data are normalized to assay
controls and constrained to 100%. Growth
patterns of control conditions are also shown (top
panel). For these data, compounds were assessed
from the original screening library stocks.
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the cytotoxicity of the hit compounds by measuring the release
of cytosolic lactate dehydrogenase (LDH; Figures 4C, 4D, and
S2C). We found that E25 rescued the MNs by 80% and with an
EC50 of 0.68 mM (Figure 4D). When tested alone, the efficiency
of inducing microglial death was directly comparable to the inhi-
bition of NO production (Figure 4D). Therefore, E25 prevents the
degeneration of MNs by selectively killing microglial cells.
Hit Compounds Stimulate Transcription of Nrf2
Target Genes
To gain additional insight into the mode of action by hit
compounds, we performed expression profiling. BV2 cells
were activated in the presence of individual hit compounds for
4 hr and compared with BV2 cells activated without any addi-624 Cell Stem Cell 11, 620–632, November 2, 2012 ª2012 Elsevier Inc.tional compounds. Hierarchical clustering
of the data revealed a tight association of
the four hit compounds E5, E14, E19, and
E20 (Figure 5A). For that reason, we then
identified the genes that were upregu-
lated in BV2 cells by all four of these hits
compared with activated BV2 cells with-
out any compound. Strikingly, we found
a cluster of genes known to be targets
of the transcription factor Nrf2 (Figure 5B).
Likewise, our similarity search results
already predicted that E14 would interact
with Nrf2 (Table S1). These results sug-
gested that Nrf2 activation is a possible
mechanism for many of our hits. To test
this, we examined the effects of two
known activators of Nrf2—tert-butylhy-
droquinone (tBHQ) and bardoxolone
(Bx)—in our MN protection assay (Fig-
ure 5C). As expected, both compounds
protected MNs from degeneration.
However, at higher concentrations, the
compounds were neurotoxic, particularly
Bx. Furthermore, as in our original hits, Bx
did not rescue MNs from DetaNO-
induced degeneration. Although tBHQ
did rescue MNs from DetaNO-induced
degeneration, it is likely that this is from
an off-target effect, because tBHQ is
known not to be specific to the Nrf2
pathway (Gharavi and El-Kadi, 2005).Next, we used quantitative RT-PCR to assess the effects of
our hit compounds on the transcription of known Nrf2 target
genes in comparison with tBHQ and Bx. Becausemicroglial cells
were required for protection, we first examined BV2 cells. The
genes Gclm, Hmox1, and Nqo1, which are known to be Nrf2
targets, were all upregulated after treatment with the hit
compounds for as little as 2 hr (Figure 5D). Moreover, the overall
time course of the upregulation of Nrf2 targets by our hit
compounds was either comparable to or better than the upregu-
lation induced by the positive-control compounds. Given the
requirement of microglial cells for neuroprotection by our hit
compounds, we also assessed the effects of our hit compounds
on the transcription of Nrf2 target genes in both MNs and astro-
cytes (Figure 5E). In both cell types, our hit compounds induced
upregulation of Gclm, Hmox1, and Nqo1 comparably to or even
Figure 4. Involvement of Microglial Cells
(A) Experimental design to assess the necessity of microglial cells for neuroprotection by hit compounds. The astrocyte-MN coculture was treated for 30 hr with
hit compound plus ether activated BV2 cells or DetaNO. Hits that depend on modulation of microglial cells for neuroprotection are expected to only rescue MNs
from activated BV2 cells (green line), but not fromDetaNO (orange line). In contrast, hits that are directly neuroprotective or act through astrocytes are expected to
protect from both stress agents.
(B) MN survival was evaluated for the indicated hit compounds in the presence of either activated BV2 cells (green line) or with DetaNO (orange line).
(C) Activated BV2 cells were incubated with hit compounds for 30 hr and tested for NO production and LDH release.
(D) Dose-response curves for the indicated hits on BV2 cells for either the production of NO, indicating activation (red line), or the release of LDH, indicating
cytotoxicity (blue line). The respective EC50 values are listed in the embedded tables. Data are normalized to assay controls and shown as mean ± SEM. The
curves for NO production (red lines) are constrained to 0%.
NA = not applicable. In contrast to Figure 3, these data were obtained with compounds that had been repurchased. See also Figure S2.
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Figure 5. Hit Compounds Stimulate Nrf2
Target Gene Expression
(A) Hierarchical clustering of whole-genome
expression data from nonactivated and activated
microglial cells as well as activated microglial cells
treated with individual hit compounds for 4 hr. The
cluster of compounds E5, E14, E19, and E20 is
highlighted (red box).
(B) Heat map from microarray data demonstrating
upregulation of Nrf2 target genes by the hit
compound cluster of E5, E14, E19, and E20. The
color bar indicates gene expression normalized to
activated BV2 control.
(C) Effect of known Nrf2 activators tert-butylhy-
droquinone (tBHQ) and bardoxolone (Bx) in the
MN survival assay with activated BV2 cells (green
line) or DetaNO (orange line). The experimental
design is shown in Figure 4A. EC50 values are
shown in the embedded table.
(D) Time course analysis of the expression of
Nrf2 target genes by BV2 cells treated with the
indicated compounds relative to nonactivated
controls.
(E) Nrf2 target gene expression in astrocytes after
8 hr and MNs after 4 hr of treatment with the
indicated compounds.
(F) Nrf2 target gene expression in G93A SOD1
(designated mSOD1 in the figure) primary astro-
cytes after 24 hr treatment with the indicated
compounds. Expression levels are normalized to
those of untreated controls.
(G) Coculture of ESC-derived MNs with primary
astrocytes expressing SOD1 G93A (designated
mSOD1 in the figure) in the presence of the indi-
cated compound. The number of motor neurons
after 3 days was quantified relative to that of
untreated cultures.
All data are shown as mean ± SEM. NA, not
applicable. Significance levels were determined
using a two-tailed Student’s t test. NS, not signif-
icant; p > 0.05; *0.05 > p > 0.01; **0.01 > p > 0.001;
***p > 0.001. qPCR statistics are listed in Table S4.
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activate a detoxification pathway for reactive oxygen and
nitrogen species including NO, the hits required microglial cells
for a response. This suggests that Nrf2 modulates the activation
state of microglial cells, which is supported by our previous
observation that activated BV2 cells produce significantly less626 Cell Stem Cell 11, 620–632, November 2, 2012 ª2012 Elsevier Inc.NO when treated with our hit compounds
compared with controls. Interestingly, at
least two studies confirm that Nrf2 inhibits
microglial activation (Koh et al., 2009;
Rojo et al., 2010). Our results show that,
under our assay conditions, this addi-
tional role is more important for inducing
neuroprotection than the classical antiox-
idant function of Nrf2.
It has been suggested that in ALS,
astrocytes become reactive and secrete
neurotoxic factors similar to microglial
cells (Julien, 2007). Coculture experi-ments have demonstrated that primary astrocytes expressing
SOD1 G93A, which causes ALS pathogenesis in patients,
secrete factors that are selectively toxic to MNs, including
ESC-differentiatedMNs (Nagai et al., 2007). It has also been sug-
gested that modulation of Nrf2 could be an effective treatment
strategy for ALS. Specifically, treatment with small molecules
Figure 6. Protection from NO-Induced Cell
Death by Hit Compound E4
(A) MN survival was evaluated for the indicated hit
compound in the presence of either activated BV2
cells (green line) or with DetaNO (orange line).
(B) NO production (red line) and LDH release (blue
line), indicating cell death, is shown for BV2 cells
incubated with the hit compound E4 for 30 hr
under activation conditions. Data are normalized
to assay controls and shown as mean ± SEM.
(C) Experimental design for validation with human
neurons. hNPC-derived neurons were treated with
200 mM DetaNO plus hit compound. Survival was
analyzed by immunostaining for neurons (TUBBIII)
after 72 hr of incubation.
(D) Validation of direct neuroprotection by E4 with
human neurons.
(E) Quantification of human neuroprotection.
Significance was determined using a two-tailed
Student’s t test. *0.05 > p > 0.01; **0.01 > p >
0.001.
See also Figure S3.
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Stem-Cell-Based Phenotypic Screeningactivating Nrf2 and overexpression of Nrf2 in astrocytes signifi-
cantly extended survival of mice expressing transgenic mutant
SOD1 (Neymotin et al., 2011; Vargas et al., 2008). To test whether
our compounds would be effective in this system, we isolated
primary astrocytes from mice expressing transgenic G93A
SOD1. We then exposed these primary astrocytes to E5, E14,
E19, or E20 without any other stimulation. As expected, the hit
compounds induced transcription of Gclm, Hmox1, and Nqo1
comparably to or even better than the controls (Figure 5F). These
results suggest that our hit compounds might rescue MNs from
astrocyte-induced degeneration induced by primary astrocytes
expressing mutant SOD1. We tested this by coculturing ESC-Cell Stem Cell 11, 620–632,derived MNs with primary astrocytes ex-
pressing SOD1 G93A in the presence of
a hit compound for 3 days and then as-
sessed the number of surviving motor
neurons relative to untreated cocultures.
We consistently observed a statistically
significant increase in motor neuron
survival in cultures treated with our hit
compounds relative to control (Figure 5G).
Consistent with our previous results, the
increase in survival was greater with our
hit compounds than with the positive
controls tBHQ and Bx. These results indi-
cate that E5, E14, E19, or E20 may be
good startingpoints for novel drugs aimed
at treating patients with ALS.
Direct Protection from NO-Induced
Cell Death by Hit Compound E4
A significant advantage of our stem-cell-
based screen is that it grants an ability
to identify compounds acting on several
different targets in a single assay. In
contrast to the above hit compounds,
which required microglial cells to induceneuroprotection, E4 protected MNs from DetaNO-induced
degeneration with 100% efficiency (Figure 6A). Interestingly,
the rescue by E4 was almost twice as potent with DetaNO-
induced degeneration compared with activated microglia-
induced degeneration (Figure 6A). In addition, the EC50 for
DetaNO-mediated toxicity, 0.23 mM, was significantly lower
than that for the microglia-mediated toxicity, 1.3 mM. These
results demonstrate that E4 protects MNs directly from
NO-induced degeneration and does not require the presence
of microglial cells to exert neuroprotection.
To rule out the possibility that E4 induced uptake and ‘‘metab-
olization’’ of NO by astrocytes, we evaluated NO levels in theNovember 2, 2012 ª2012 Elsevier Inc. 627
Figure 7. Role of Astrocytes in Neuroprotection
(A) Outline of the experimental procedure to assess the role of astrocytes. FACS-isolated MNs were cocultured with activated BV2 cells and hit compound, but
without astrocytes. MN survival was analyzed after 30 hr.
(B) The dose-response curves for MN survival are shown for the indicated hit compounds. The respective EC50 values are listed in the embedded tables. Data are
normalized to controls and shown as mean ± SEM.
Cell Stem Cell
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Stem-Cell-Based Phenotypic Screeningpresence of only astrocytes and no neurons. However, no signif-
icant effect was observed (Figure S3). These results also indi-
cated that compound E4 did not chemically neutralize NO, in
contrast to known NO scavengers such as 2-4-carboxyphenyl-
4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (Osiecki and Ull-
man, 1968). E4 also reduced the production of NO by activated
microglial cells. The NO level in the presence of E4 was 16.5%
compared to control, and the EC50 of this effect was 3.9 mM (Fig-
ure 6B). No significant cell death was observed at the EC50
concentrations, indicating that E4 did not induce the death of mi-
croglia (Figure 6B). This demonstrates that E4 not only inhibits
the NO sensitivity of neurons, but also directly or indirectly
inhibits the generation of NO in microglial cells. Given the limited
information currently available on the biochemical function of E4,
it is not possible to give mechanistic details about these dual
functions within the same molecule.
For further validation, we used human neurons differentiated
from human ESCs to assess neuroprotection of E4 from DetaNO
(Figure 6C). As with the mouse neurons, 200 mM DetaNO
induced the degeneration of human neurons. In contrast, E4
induced a dose-depended rescue of the human neurons from
DetaNO (Figures 6D and 6E). These results correlated well with
the increased survival rates of mouse MNs. Therefore, we
conclude that E4 directly induces rescue of neurons, including
human neurons, from NO-induced degeneration.
The Role of Astrocytes in Neuroprotection
Astrocytes play an important role in the pathology of ALS both
in vitro and in vivo. To determine whether astrocytes are required
for neuroprotection by hit compounds, we developed an astro-
cyte-free version of our microglial toxicity assay. FACS-isolated
motor neurons were cultured in the presence of activated BV2
cells for 30 hr followed by quantification of MN survival using
high-content imaging (Figure 7A). We consistently observed
that all hit compounds tested were neuroprotective in the
absence of astrocytes, which demonstrates that astrocytes are
not required for neuroprotection (Figures 7B and S4). Because
microglial cells are not required for E4 activity, we also tested
for neuroprotection by E4 using FACS-sorted MNs and DetaNO.
Consistent with previous results, neuroprotection was directly
induced by E4 (Figure S4). As expected, all compounds demon-
strated toxicity to MNs at high concentrations.
Although neuroprotection could be conferred in the absence
of astrocytes by all tested compounds, we consistently
observed a significant decrease in the toxicity of activated mi-
croglial cells when astrocytes were removed. In the original
assay, which included astrocytes, after 30 hr there were virtually
no MNs left (Figure 7C). Almost all neurites had degenerated
under those conditions. In contrast, in the absence of astrocytes,
30 hr after coculture with activated microglial cells, many MNs(C) Fluorescent images showing Hb9-GFP MNs cultured with or without astrocyte
microglia (lower and upper panels, respectively).
(D) Quantification of Figure 7C. Results are normalized to nonactivated, which w
(E) Hierarchical clustering of whole-genome data from nonactivated astrocytes, as
indicated hit compound for 4 hr. E29 clusters are close to the nonactivated cont
(F and G) Expression analysis of IFN-g-induced genes Gm4841 andGbp10 (F) an
cultured under the indicated conditions.
Significances were determined using a two-tailed Student’s t test. NS, not sign
applicable. See also Figures S4 and S5.
Cellstill had neurites, signifying more moderate degeneration (Fig-
ure 7D). Taken together, these data suggest that astrocytes syn-
ergize with microglial cells and exacerbate MN degeneration.
Because primary astrocytes are known to become inflamma-
tory under the same conditions that were used in our assay, we
performed expression profiling of NSC-derived astrocytes under
nonactivating and activating conditions. Interestingly, we
observed that treatment of astrocytes with LPS and IFN-g
induced expression of inflammatory markers such as Il6, Tnfa,
iNos, and Stat1 (Figure S5A). As a result, we profiled the expres-
sion of astrocytes treated with hit compounds. Hierarchical
clustering of the results demonstrated that hit E29 clustered
significantly closer to the nonactivated astrocytes than to the
activated astrocytes (Figure 7E). Analysis of the differentially ex-
pressed genes confirmed that E29 inhibited the induced expres-
sion of many inflammatory mediators in astrocytes activated by
LPS and IFN-g (Figure S5A). Because microglial activation is
similar to astrocyte activation, we profiled the microglial cells
activated in the presence of E29 and compared them with both
nonactivated and activated BV2 cells (Figure S5B). E29 inhibited
the induced expression of many inflammatory mediators in BV2
cells, although not to the same extent as in astrocytes. Assaying
LDH release by astrocytes treated with E29 demonstrated that
the observed decrease in the expression of inflammatory
markers was not due to toxicity (Figure S5C).
Because E29 inhibited the activation of both astrocytes and
microglial cells, we sought to determine if the compound acted
by directly inhibiting either toll-like receptor 4 (Tlr4) or the IFN-g
receptor (Ifngr), which are the receptors for LPS and IFN-g,
respectively. We treated BV2 cells and NSC-derived astrocytes
independently with LPS, IFN-g, or both, and then performed
quantitative RT-PCR for specific marker genes. In astrocytes
and microglial cells, IFN-g, but not LPS, specifically induced
expression of Gm4841 and Gbp10 (Figure 7F). E29 inhibited
the upregulation of both of these markers in response to IFN-g.
However, in BV2 cells, LPS specifically induced the expression
of Il1b, Il6, iNos, andTnfa, whichwas inhibited byE29 (Figure 7G).
NSC-derived astrocytes induced less upregulation of Il1b, iNos,
and Tnfa in response to LPS treatment compared with BV2 cells,
which could be due to a variety of factors including maturation
state. Therefore, taken together, our findings indicate that E29
inhibits both Tlr4- and Ifngr-induced transcription activation
and is not specific to either one or the other.
DISCUSSION
Phenotype-based screens lead to the discovery of more first-in-
class drugs than target-based approaches. Although primary
cells would be the ideal reagent for phenotypic assays, primary
cells, particularly from human patients, are unavailable ins (left and right panels, respectively), cocultured with nonactivated or activated
as set as 100%.
trocytes activatedwith LPS and IFNg, and activated astrocytes treatedwith the
rol (red box).
d LPS-induced genes Il1b, Il6, iNos, and Tnfa by microglial cells and astrocytes
ificant; p > 0.05; *0.05 > p > 0.01; **0.01 > p > 0.001; ***p > 0.001; NA, not
Stem Cell 11, 620–632, November 2, 2012 ª2012 Elsevier Inc. 629
Cell Stem Cell
Stem-Cell-Based Phenotypic Screeningsufficient quantities and homogeneity for HTS. Transdifferentia-
tion, which is induced by the expression of specific transcription
factors, has been proposed as a possible alternative. However,
induced transdifferentiation generally results in postmitotic cells
that are incapable of clonal expansion, such as induced MNs
(Son et al., 2011). Without expansion, transdifferentiation leads
to the production of very limited numbers of cells that are
not sufficient for screening. Stem cells, in contrast, are capable
of significant expansion and differentiation into cell types that
function comparably to primary cells. To further enable large-
scale HTS, we have subsequently optimized an assay protocol
that lacks the time-consuming FACS purification of motor
neurons used in our pilot screen. Both protocols are detailed in
the Experimental Procedures. Therefore, at present, stem cells
offer an attractive alternative for phenotype-based screening.
Our work provides powerful validation that this concept actually
works.
Microglial activation and neuronal degeneration are hall-
marks of many neurodegenerative diseases, including ALS,
Huntington’s disease, and Parkinson’s disease. We have devel-
oped an assay to identify small molecules that inhibit neuronal
degeneration induced by activated microglial cells. We demon-
strated that it is possible to detect hits acting through multiple
different pathways in a single assay. To discriminate between
the different modes of action, we also developed secondary
cell-based assays. For example, compound E4 both directly
protected neurons from DetaNO toxicity and reduced microglial
production of NO. We found that E25 reduced the production of
neurotoxic compounds such as NO by inducing cell death in
microglia. Another group of compounds modulated the activa-
tion of microglial cells, reducing the production of NO and
thereby rescuing the neurons. We found that the four hit
compounds E5, E14, E19, and E20 activated the Nrf2 pathway.
Interestingly, these hits induced neuroprotection by modulating
the activation state of microglial cells instead of directly
inducing expression of detoxification genes in motor neurons.
Activation of this pathway has previously been shown to be
therapeutic in animal models of neurodegenerative diseases,
including ALS, Parkinson’s disease, and Alzheimer’s disease
(Jazwa et al., 2011; Li et al., 2012; Neymotin et al., 2011).
This suggests that our hit compounds would be good starting
points for new drugs treating a wide range of neurodegenera-
tive diseases.
A significant challenge with cell-based phenotypic screenings
will be determining the molecular target of the compounds.
Target-based screens utilize biochemical assays with purified
proteins. As such, it is very unusual to not know the intended
target of the compound. In contrast, cell-based phenotypic
screens are complex systems, and, as a result, the identified
compoundswill almost always require subsequent target decon-
volution. Target deconvolution generally involves strategies such
as pulldowns and siRNA testing, which are potentially time
consuming and cumbersome. Given the relatively large numbers
of hits that can be discovered in a phenotypic screen, such
screening campaigns may need to involve fewer compounds
than the traditional biochemical screens. Another strategy might
be to first run pilot screens such as ours to determine a particular
mechanism of interest and then focus larger screening efforts on
that mechanism.630 Cell Stem Cell 11, 620–632, November 2, 2012 ª2012 Elsevier InIn conclusion, we report the generation of a stem-cell-based
phenotypic assay that is suitable for HTS. We discovered
small molecules acting in multiple and distinct pathways. In
addition, we confirmed the activity of these compounds on
human neurons. Considering that aberrant microglial activation
is thought to play a role in multiple neurodegenerative disorders,
the hits compounds identified here could be of interest in the
development of therapeutic agents for multiple neurological
diseases.
EXPERIMENTAL PROCEDURES
Screening Assay
HB9-GFP ESCs were derived from GENSAT mice [Tg(Mnx1-EGFP)
GX229Gsat/Mmcd] carrying a transgenic BAC containing a GFP reporter
under the control of the HB9 promoter. The ESCs were maintained feeder-
free in ESC medium and differentiated into MNs as described in Wichterle
et al. (2002) with minor modifications. Embryoid bodies (EBs) were formed
by plating single-cell ESCs on Petri dishes in DK10 medium. Starting on day
2, the medium was supplemented with 1 mM retinoic acid (Sigma-Aldrich)
and 1 mg/ml purmorphamine (Alexis Biochemicals). On day 6 of differentiation,
EBs were disaggregated. GFP-positive MNs were isolated by FACS and
plated on either NSC-derived astrocytes or Matrigel (BD Biosciences)-coated
384-well plates as indicated. Alternatively, EBswere dissociated and plated on
astrocytes without sorting by FACS. The astrocytes were generated from
NSCs previously derived from Do et al. (2007). NSCs were differentiated
with astrocyte medium containing 10% FCS. On day 4, the differentiating
NSCs were replated on Matrigel-coated 384-well plates. The astrocytes
were matured for 14 days. BV2 cells (Blasi et al., 1990) were activated with
1 mg/ml LPS (Sigma-Aldrich) and 10 ng/ml IFN-g (PeproTech). As indicated,
BV2 cells or DetaNO (Sigma-Aldrich) was added to the assay plates 1 day after
the addition of MNs. Motor neurons were analyzed 30 hr after the addition of
either BV2 cells or DetaNO using the Opera High Content Imaging and Anal-
ysis platform (Perkin Elmer) and the Arrayscan VTI Live (Thermo Scientific,
Cellomics). For quantification of images, the CSIRO Neurite Outgrowth evalu-
ation module in an Acapella-based script for Opera images, and the Cello-
mics Bioapplication Neurite Profiling for images from the Array Scan, both
generating multiple readouts (including total neurite length and number of
branch points) were used. Screening compounds were added simultaneously
with the microglial cells or DetaNO. Each well (X) was normalized to internal
plate controls [low control (L; 0%): activated BV2s or DetaNO, only DMSO;
high control (H; 100%): nonactivated BV2s or no DetaNO, only DMSO] and ex-
pressed as a percent: MN survival [% CTRL] = (X  L)/(H  L)*100. Animal
handling was conducted in accordance with the Max Planck and Evotec AG
animal protection guidelines and the German animal protection laws. For addi-
tional details on cell derivation, culturing, differentiation, and screening, see
Supplemental Experimental Procedures.
Human Validation Assay
Human neural precursor cells (hNPCs) were derived from human pluripotent
stem cells (hPSCs) according to the modified protocol from Chambers et al.
(2009) and propagation was performed similar to Koch et al. (2009). For details
see Supplemental Experimental Procedures. For neuronal differentiation,
hNPCs were seeded overnight on Matrigel-coated dishes in NPC expansion
medium. Differentiation was initiated with NPC differentiation medium supple-
mented with 0.5 mM dibutyryl-cAMP. Screening was performed after 14 days
of differentiation. See Supplemental Experimental Procedures for additional
information.
Quantification of NO Production
NOwasmeasured indirectly by detecting the degradation of the product nitrite
(Griess assay; Green et al., 1982). Culture media was added to Griess reagent
(Sigma-Aldrich) in a 1:1 ratio. After incubating at room temperature for 15 min,
the absorbancewasmeasured at 540 nm. Experimental values were corrected
for background nitrite content in the media and calculated as percentage of
controls.c.
Cell Stem Cell
Stem-Cell-Based Phenotypic ScreeningCytotoxicity Determination
Cytotoxicity was measured by the release of cytosolic LDH by dead and dying
cells using the Cytotoxicity Detection KitPlus (LDH) (Roche Applied Science) ac-
cording to the manufacturer’s instructions and as detailed in the Supplemental
Experimental Procedures.
RT-qPCR and Microarray Analysis
Cells for RNA isolation were lysed in the culture wells. Reverse transcription
was performed with MMLV enzyme (USB) and oligo dT15 priming. qPCR
was carried out using SYBR Green master mix (ABI). Calculations were based
on the DDCt method normalized to a housekeeping gene. Primer sequences
used for subsequent confirmation studies are shown in Table S5. cDNA
samples for global gene expression analysis were prepared with the linear
TotalPrep Amplification Kit (Ambion). Hybridization on mouse-8 V2 chips
(Illumina) was carried out as recommended by themanufacturer. Data analysis
was done in Illumina genome studio and MS Excel.
ACCESSION NUMBERS
Microarray results are accessible at the GEO database under accession
number GSE37611, in a MIAME-compliant format.
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes five figures, five tables, and
Supplemental Experimental Procedures and can be found with this article
online at http://dx.doi.org/10.1016/j.stem.2012.07.005.
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